The US Patent and Trademark Office has granted a patent for BioMarck Pharmaceuticals' core technology in a novel treatment for respiratory diseases associated with mucus hypersecretion and inflammation, currently in clinical trials.

BioMarck Pharmaceuticals has licensed worldwide exclusive rights for this patent and related patents from North Carolina State University. The new patent provides broad protection for a series of first-in-class mucus inhibiting peptides and the methods of treatment for a variety of pulmonary diseases involving mucus hypersecretion. A European patent and a series of international patents are allowed while others are pending.

Indu Parikh, BioMarck's president and chief scientific officer, said that  this patent significantly strengthens its overall intellectual property portfolio.